Genetic analysis of the biosynthesis of pharmaceutically important dihydroergot alkaloids by heterologous expression of Claviceps gigantea genes in the fungus Neosartorya fumigata Ergot alkaloids are a family of secondary metabolites produced by several species of fungi. The structural similarities of ergot alkaloids to neurotransmitters give them the ability to help treat several neurological and cognitive diseases, such as dementia, Alzheimer's and Parkinson's disease. These pharmaceuticals are currently being synthesized from more complex ergot alkaloids, however they would be more efficiently synthesized from dihydroergot alkaloids. Understanding the genes involved in the synthesis of dihydroergot alkaloids, such as dihydrolysergol and dihydrolysergic acid, and elucidating their pathways will be beneficial. The Mexican maize ergot pathogen Claviceps gigantea has been reported to produce dihydrolysergol, which is an oxidized product of the precursor ergot alkaloid festuclavine. Due to the discovery of an ergot alkaloid synthesis gene, cloA, catalyzing multiple oxidations on a similar substrate, it was hypothesized that expression of C. gigantea cloA in a festuclavine-accumulating mutant of the model fungus Neosartorya fumigata would yield dihydrolysergol. HPLC and LC-MS analyses of the cloA transformed strains, demonstrated that the modified strain produced dihydrolysergic acid, the fully oxidized product of dihydrolysergol. Since dihydrolysergol was expected to be the pathway end product of C. gigantea, the genomic sequence data was analyzed and extracts of fieldgrown C. gigantea. The natural alkaloid analysis results supported the finding that dihydrolysergic acid is the end product of the C. gigantea pathway, rather than dihydrolysergol. C. gigantea is the first organism demonstrated to produce the pharmaceutically important compound dihydrolysergic acid as its pathway end product and heterologous expression of its cloA gene may serve as the basis of a more efficient approach to production of DHLA for pharmaceutical purposes. Additional attempts to increase the yield of dihydrolysergic acid in our modified strain, such as removal of introns, expression from an alternative promoter, and coexpression with an additional ergot alkaloid synthesis gene, easA, were conducted. The removal of introns and the alternative promoter had no significant effect on the yield of dihydrolysergic acid compared to the original cloA transformants in ANOVA (p = 0.58 and p = 0.76). However, the mutants expressing cloA-easA had conversion rates two-fold higher than the mutants expressing cloA (p = 0.01). The data illustrate that CloA of C. gigantea catalyzes a six-electron oxidation of festuclavine to dihydrolysergic acid.
Literature Review/Introduction

Ergot Alkaloids
Ergot is a fungal infection caused by Claviceps species that affect rye, wheat, corn, and several other monocot plants. Ergot alkaloids are agriculturally and pharmaceutically important, though many Claviceps species produce ergot alkaloids, which have caused mass poisonings, called ergotism, as a result of accumulations of these alkaloids in grain crops. Ergot alkaloids also have caused reduced weight gain and fitness in grazing animals as a result of their accumulation in related endophytic fungi (Epichloë species) that colonize forage grasses (Robinson and Panaccione, 2014) . However, in 1918, Sandoz marketed ergot alkaloids as bulk pharmaceutical chemicals, when it was discovered they had clinical uses (Schiff, 2006) . Many fungi in the genus Claviceps (in the family Clavicipitaceae) produce a variety of ergot alkaloids, including clavines and lysergic acid derivatives. A different set of ergot alkaloids are produced by the distantly related fungus Neosartorya fumigata, from the family Trichocomaceae. Over 80 distinct types of ergot alkaloids have been isolated, mainly from the genus Claviceps (Schiff, 2006) . Ergot alkaloids are a family of secondary metabolites and represent the largest group of nitrogenous fungal metabolites in nature (Schiff, 2006) . Ergot alkaloids are limited to a narrow set of species, such as those found in the families Clavicipitaceae and Trichocomaceae, so they have a limited distribution in nature. Ergot alkaloids play a role in plant defense, because they have harmful effects on vertebrate and invertebrate herbivores Potter et al., 2008) .
Ergot alkaloids are small molecules that are heavily derivatized from the amino acid tryptophan. Tryptophan is an indole derivative and is a precursor to the neurotransmitter serotonin.
Ergot alkaloids also have structural similarities to the neurotransmitters dopamine, adrenaline, and noradrenaline, making them useful pharmaceuticals. Ergot alkaloids' pharmaceutical effects are the result of their agonism or antagonism at serotonergic, dopaminergic, and adrenergic receptors in the central nervous system, as well as at adrenergic receptors in blood vessels (Schiff, 2006; Gerhards et al., 2014) . This allows ergot alkaloids to be used clinically to treat several neurological and cognitive diseases, such as migraines, dementia, Alzheimer's, and Hyperprolactinemia (Morren and Galvez-Jimenez, 2010; Baskys and Hou, 2007; Winblad et al., 2007; Kerr et al., 2010 ; Table 1 ). Several important pharmaceuticals are semisynthetic derivatives of dihydrolysergic acid or its intermediate dihydroelymoclavine (i.e. dihydrolysergol), which are ergot alkaloids rarely encountered in nature; therefore elucidating their biosynthetic route would be beneficial (Bilovol and Panaccione, 2016;  Fig. 1 ; Table 1 ). 
Ergot Alkaloid Pathway
Individual species in two major fungal families, Clavicipitaceae and Trichocomaceae, are known to produce ergot alkaloids. All fungi that produce ergot alkaloids share the same early biosynthetic steps that lead to the formation of the ergoline ring structure, before diverging into specific ergot alkaloid lineages (Coyle et al., 2014) . For the production of all ergot alkaloids, the ergot alkaloid synthesis (eas) genes that are involved are all found in clusters in each genome of the producing organism. No gene that is critical to the production of ergot alkaloids is located outside of an eas gene cluster (Bilovol and Panaccione, 2016) . Modifications to the ergoline rings by enzymes in the eas gene cluster results in chemical products that are used as the basis for pharmaceutical drugs. Gene clusters from several fungi have been elucidated through genome mining, knock-out experiments, and overexpression experiments (Gerhards et al., 2014) .
The ergot alkaloid pathway in both Claviceps species and N. fumigata is initiated by the prenylation of tryptophan, which is catalyzed by dimethylallyltryptophan synthase encoded by the gene dmaW (Fig. 2) . Coyle et al. (2010) demonstrated that chanoclavine-I-aldehyde is the last shared intermediate in the ergot alkaloid pathway for Claviceps and N. fumigata (Fig. 2) . The branch point between these pathways occurs during the D ring closure, as a result of the products of different alleles of easA have functional differences. EasA is an oxidoreductase of the 'old yellow enzyme' class, which reduces double bonds that are conjugated to either aldehydes or ketones. In the ergot alkaloid pathway, EasA reduces the double bond conjugated to the aldehyde group of chanoclavine-I-aldehyde, which allows for ring closure by Schiff base formation . In N. fumigata, the 8,9 double bond in chanoclavine-I-aldehyde is reduced by the reductase form of EasA (Fig. 2) . The derived iminium ion is further reduced by EasG to form festuclavine, which can be acetylated at carbon 2 and/or prenylated at carbon 9 to produce fumigaclavine derivatives ( Fig. 2) (Wallwey et al., 2010; Cheng et al., 2010) . In most Claviceps species, an isomerase form of EasA transiently reduces chanoclavine-I-aldehyde before reoxidizing it to produce the 8,9 unsaturated agroclavine ( Fig. 2) . In C. purpurea
and Epichloë species agroclavine is oxidized to produce elymoclavine, elymoclavine is further oxidized and isomerized to produce lysergic acid, and lysergic acid is assimilated into ergopeptines and/or lysergic acid amides ( Fig. 2) (Robinson and Panaccione, 2014) . As a result of this major difference, fungi in the family Clavicipitaceae synthesize lysergic acid derivatives, in which carbons 9 and 10 in the D ring of the ergoline ring structure are unsaturated and carbon 17 is oxidized ( Fig. 2) Schardl et al., 2006; Lorenz et al., 2009) . Fungi in the family Trichocomaceae synthesize clavine derivatives, in which carbons 9 and 10 in the D ring are fully saturated and carbon 17 remains as a methyl group (Fig. 2) (Panaccione et al., 2012; Wallwey and Li, 2011) . Lysergic acid derivatives are produced exclusively by the family Clavicipitaceae and not by model organisms, like N. fumigata, in which their modification might be facilitated (Robinson and Panaccione 2014) . Coyle et al. (2010) also created two mutant strains of N. fumigata. The first was an easA knockout strain, which was created by integrating pAFOYE1, along with the hygromycin resistance plasmid pMOcosX, into easA (reductase) in order to disrupt its function. The disruption construct, pAFOYE1, contained a 595 bp fragment from the 1,131 bp coding sequence of easA from N. fumigata ligated into the T/A overlap vector pCR2.1. This mutant strains pathway ended at chanoclavine-I-aldehyde, which is the last common intermediate between the fumigaclavine C and lysergic acid pathways. This strain was also beneficial, because it allowed Coyle et al. (2010) to investigate the functions of easA isomerase compared to easA reductase. By cotransforming easA isomerase from C. purpurea along with pBC-phleo, a phleomycin resistance plasmid, into the easA KO strain, they were able to modify the ergot alkaloid profile. Instead of detecting the usual alkaloids such as festuclavine and fumigaclavines A,B, and C, they detected setoclavine, isosetoclavine, and large amounts of agroclavine ).
Robinson and Panaccione (2014) engineered a strain of N. fumigata to transform agroclavine into lysergic acid (Fig. 2 ). This was done by using an N. fumigata easA knockout strain as host fungus, so that the pathway stopped at chanoclavine-I-aldehyde. A construct containing easA (isomerase) and a second gene, cloA, both from an Epichloë species, was transformed into the N. fumigata easA knockout strain, so that the EasA isomerase converted chanoclavine-Ialdehyde into agroclavine and CloA converted agroclavine into lysergic acid. The gene cloA, which stands for clavine oxidase, was required for complete oxidation of carbon 17 of both agroclavine and elymoclavine during the synthesis of lysergic acid (Fig. 2) . The gene encodes a P450 monooxygenase and is only found in fungi that produce lysergic-acid derivatives (Robinson and Panaccione, 2014) . It was concluded that CloA catalyzes a six-electron oxidation of agroclavine to lysergic acid and that either CloA or EasA isomerizes the 8,9 double bond in the D ring to the 9,10 position. CloA had multiple catalytic activities, including a two-electron oxidation of agroclavine to elymoclavine and an additional two sets of two-electron oxidations to convert elymoclavine to lysergic acid. The lack of detectable elymoclavine in the extracts of the developed strain indicated that CloA could execute successive oxidations and an isomerization without releasing the substrate (Robinson and Panaccione, 2014) .
Two species from Clavicipitaceae, Claviceps gigantea and Claviceps africana, have been reported to produce dihydroergot alkaloids, however the genes involved in their biosynthetic pathways have not been investigated. Dihydroergot alkaloids differ from lysergic acid-derived alkaloids due to carbons 9 and 10 being saturated and carbon 17 being oxidized (Bilovol and Panaccione, 2016) , giving them different, unique pharmaceutical properties. These species are similar to N. fumigata, due to chanoclavine-I-aldehyde being reduced by EasA reductase to produce festuclavine. Barrow et al. (1974) investigated the dihydroergot alkaloid pathway through an approach based on feeding labeled precursors to the fungus Claviceps africana. They showed that the dihydroergot alkaloid pathway in C. africana and by extension C. gigantea proceeded from festuclavine to dihydroelymoclavine to dihydrolysergic acid to dihydroergosine (Fig. 2) . It is predicted that festuclavine could be transformed into dihydroelymoclavine then dihydrolysergic acid by oxidizing carbon 17, analogous to the agroclavine to lysergic acid pathway.
Dihydrolysergic acid derivatives are also solely produced by the family Clavicipitaceae and not by model organisms, such as N. fumigata, in which their modification may be facilitated (Robinson and Panaccione, 2014) . Many of the genes that are necessary in the biosynthesis of the lysergic acid-derived ergot alkaloids have been characterized, but the genes that are necessary in the synthesis of dihydroergot alkaloids have yet to be studied (Bilovol and Panaccione, 2016) . Among the genes in the eas cluster, cloA is the reasonable candidate to conduct the first oxidation of carbon 17 of festuclavine to produce dihydroelymoclavine, due to the discovery of its catalytic functions on a similar substrate, agroclavine (Robinson and Panaccione 2014) .
Figure 2:
Lysergic acid pathway (left; Robinson and Panaccione, 2014) , predicted dihydroergot alkaloid pathway (middle; Barrow et al., 1974) , and fumigaclavine pathway (right; Bilovol and Panaccione, 2016) .
Both intermediates and products are shown along with the enzymes responsible (indicated next to arrows). Double arrows express the omission of one or more intermediates. The ergoline ring structure is shown in the top right for reference to descriptions in text.
In N. fumigata, festuclavine is transformed into fumigaclavines through the hydroxylation and acetylation of carbon 2 and/or the prenylation of carbon 9 (Fig. 2) . The gene easM encodes for the festuclavine-hydroxylating enzyme, which hydroxylates festuclavine into fumigaclavine B (Fig. 2 ). Bilovol and Panaccione (2016) prepared an easM knockout strain of N. fumigata, so the ergot alkaloid pathway stops at and accumulates large quantities of festuclavine (30.9 amol/conidium). The strain was derived by replacing part of the easM coding sequence with a hygromycin resistance gene, in order to disrupt the gene's function. This development is beneficial, because festuclavine is the last common intermediate in both the fumigaclavine branch in N. fumigata and in the dihydroergot alkaloid pathway in certain Claviceps species. This mutant strain will be useful for studying genes important in the synthesis of dihydroergot alkaloids, since festuclavine is the precursor to dihydroergot alkaloids (Bilovol and Panaccione 2016) . The candidate gene, cloA, was tested through expression in an N. fumigata easM knockout (easM KO) strain and an N. fumigata easA knockout (easA KO) strain.
Claviceps gigantea
A new species of Claviceps was described in the 1960s (Fuentes et al. 1964 ). The fungus grew on maize and was reported due to the toxic effects it caused when ingested. The fungus is recognized by the large, soft sclerotia that replace the kernels on maize. Large numbers of microconidia occur on the sclerotia, and they were isolated to prove they were the etiological agent (Ullstrup, 1973) . The sclerotia produced the typical stipe and stroma of other Claviceps species, however, they were much larger than any other described species, so the new species Claviceps gigantea was described. C. gigantea has a very limited geographical distribution and is only found at high altitudes in Mexico, where the climate is cool and humid (Ullstrup, 1973) .
C. gigantea was studied for ergot alkaloids in Agurell and Ramstad's work in 1965. Festuclavine and dihydroelymoclavine (synonym dihydrolysergol) were two alkaloids isolated from the sclerotia of the fungus. This was the first time dihydrolysergol was isolated from a natural source, and it is relevant because dihydrolysergol is closely related to dihydrolysergic acid. For example, it had previously been chemically cleaved from dihydrolysergic acid methyl ester (Agurell and Ramstad, 1965) . Overall, most species of Claviceps produce derivatives of lysergic acid. However, it is believed that C. gigantea is capable of producing other dihydroergot alkaloids, based on the isolation of dihydrolysergol from the fungus. This fungus may be an appropriate genetic resource for studies on dihydroergot alkaloid biosynthesis.
Rationale and Hypothesis
Though many steps in the ergot alkaloid pathways have been clarified, the dihydroergot alkaloid pathway remains to be elucidated. As a result, dihydroelymoclavine and dihydrolysergic acid used for pharmaceutical purposes must be chemically modified from more complex, naturally occurring ergot alkaloids. The easM knockout strain of N. fumigata created by Bilovol and Panaccione (2016) is the ideal host for my planned experiment, since it accumulates high amounts of festuclavine, which is the precursor to dihydroergot alkaloids (Barrow et al., 1974) .
Additionally, the discovery of the multiple catalytic functions of the enzyme CloA make it a reasonable candidate to oxidize carbon 17 of festuclavine to transform it into dihydroelymoclavine or dihydrolysergic acid. I intend to test the gene cloA from the fungus C. gigantea, due to this fungus being reported to produce dihydroelymoclavine. Therefore, it is hypothesized that cloA from C. gigantea introduced into the easM knockout strain of N. fumigata will result in the oxidation of festuclavine into dihydroelymoclavine or perhaps dihydrolysergic acid (Fig. 2) . The objective of this project is to modify a strain of N. fumigata to produce dihydroelymoclavine or dihydrolysergic acid as its final product. This was done by transforming the gene cloA from C.
gigantea into the festuclavine-accumulating easM knockout strain of N. fumigata.
Materials and Methods
C. gigantea gene cluster
The C. gigantea eas gene cluster ( Figure 9B ) was identified by querying the genome's sequence with individual eas genes from other Claviceps species. Additional eas genes were identified by blastx comparisons to the nonredundant nucleotide database at NCBI.
C. gigantea natural alkaloid analysis
C. gigantea sclerotia samples were obtained from Montecillo, Mexico (Fig. 3) . The head of the sclerotia was pulverized with 10 glass beads (3-mm diameter) in 300 µL of HPLC-grade methanol by a Fastprep 120 (Bio101, Carlsbad, CA) for 30s at 6 m/s. Alkaloids were extracted for 1 hour, then the sample was pelleted by centrifugation and 20 µL of supernatant was analyzed by HPLC with fluorescence detection. 
Resequencing of pseudogene lpsA from C. gigantea
Part of the pseudogene lpsA was amplified from C. gigantea genomic DNA using primer combination 14 (Table 2) using Phusion high-fidelity polymerase (Thermo Fisher, Waltham, MA).
The fragment contained 743 bp corresponding to nucleotides 3997 to 4739 in the lpsA coding sequence and contained the suspected frameshift mutation (GenBank: KY906251). Phusion polymerase creates products with blunt ends, so the amplified product was purified (Qiagen) and ligated into SmaI-digested pUC18. This construct was then transformed into Escherichia coli, plasmid prepped (Qiagen), and sequenced to confirm frameshift mutation found during the characterization of C. gigantea's eas gene cluster (Eurofins, Louisville, KY).
Preparation of transformation constructs
Four different constructs were prepared in attempts to accumulate and increase the yield of dihydrolysergic acid (Fig. 5 ). The first construct contained cloA from C. gigantea and a bidirectional easA-easG promoter from N. fumigata (Fig. 4, Fig. 5A ). The second construct contained an intron free version of cloA from C. gigantea and the bidirectional easA-easG promoter from N. fumigata (Fig. 4, Fig. 5B ). The third construct contained an intron free version of cloA from C. gigantea and a strong gpdA promoter from N. fumigata (Fig. 4, Fig. 5C ). The fourth construct contained an intron free version of cloA from C. gigantea, the bidirectional easA-easG promoter from N. fumigata, and easA from C. gigantea (Fig. 4, Fig. 5D ). All of the PCR amplifications used Phusion high-fidelity polymerase (Thermo Fisher, Waltham, MA) and
followed the same protocol, with an initial denaturation at 98°C for 30s, followed by 35 cycles of 98°C (15 s), AT°C (15 s), and 72°C (ET s), and a final extension at 72°C for 60s (AT=annealing temperature, ET=extension time, Table 2 ). The 25 µL PCR mixture contained 11 µL distilled/deionized water, 5 µL 5x buffer ( 
C. gigantea cloA construct
To test whether CloA from C. gigantea would catalyze oxidation of festuclavine, an easA/easG promoter-cloA construct was prepared ( Fig. 5A ), for expression of cloA, in a festuclavine-accumulating easM knockout strain of N. fumigata. Primer combination 1 was used for amplification of cloA from C. gigantea genomic DNA (Tooley et al., 2006) by PCR ( Fig. 4 , Table 2 ). The reverse primer in the combination was assembled with an oligonucleotide that contained a HindIII restriction site (AAGCTT) near its 5' end to facilitate cloning of the product (Fig. 5A ). Primer combination 2 was used for PCR amplification of the easA-easG promoter from N. fumigata wild type strain Af293 (Fig. 4 , Table 2 ). The forward primer in the combination was assembled with an oligonucleotide that contained an XbaI restriction site (TCTAGA) near its 5' end ( Fig. 5A ). The two fragments were joined by adding equimolar amounts of the two initial PCR products into a fusion PCR, using primer combination 3 ( Fig. 4 , Table 2 ) to form a construct for expressing C. gigantea cloA in N. fumigata (Fig. 5A ). The easA/easG promoter-cloA construct was double-digested with HindIII and XbaI, then ligated into HindIII/XbaI-digested pBC-phleo (Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for phleomycin resistance after fungal transformation (Fig. 5A ). The plasmid was transformed into E. coli, plasmid prepped (Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic digests and DNA sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then transformed by established methods (Robinson and Panaccione, 2014) into the festuclavine-accumulating easM knockout strain of N. fumigata.
C. gigantea intron free cloA construct
To test whether an intron free version CloA from C. gigantea would better convert festuclavine to dihydrolysergic acid, an easA/easG promoter-intron free cloA construct was prepared ( Fig. 5B) for expression in the same N. fumigata easM knockout strain. Primer combination 4 was used to amplify an intron version of cloA with easA-easG promoter and 3'UTR extensions from the 1,524 bp cDNA (see mRNA analysis) ( Fig. 4 , Table 2 ). Due to the cDNA not having the cloA 3' UTR, a cloA 3'UTR segment with cloA extension was also individually amplified from C. gigantea DNA using primer combination 5 ( Fig. 4 , Table 2 ). The reverse primer in the combination was assembled with an oligonucleotide that contained an EcoRI restriction site (GAATTC) near its 5' end to facilitate cloning of the product (Fig. 5B ). The 5' UTR was included in the bidirectional easA/easG promoter, so it did not need individually amplified. Primer combination 2 was used for PCR amplification of the easA-easG promoter with cloA extension from N. fumigata wild type strain Af293 (Fig. 4 , Table 2 ). The forward primer in the combination was assembled with an oligonucleotide that contained an XbaI restriction site (TCTAGA) near its 5' end ( Fig. 5B ). The three fragments were joined by adding equimolar amounts into a fusion PCR, using primer combination 6 ( Fig. 4 , Table 2 ) to form a construct for expressing a fully processed version of cloA from C. gigantea in N. fumigata (Fig. 5B ). The easA/easG promoter-intron free cloA construct was double-digested with EcoRI and XbaI, then ligated into EcoRI/XbaI-digested pBC-phleo (Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for phleomycin resistance after fungal transformation (Fig. 5B ). The plasmid was transformed into E. coli, plasmid prepped (Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic digests and DNA sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then transformed with the same methods, into the festuclavine-accumulating easM KO.
C. gigantea gpdA promoter construct
To test whether a stronger promoter from N. fumigata would increase expression of cloA in attempts to increase conversion of festuclavine to dihydrolysergic acid, a gpdA promoter-intron free cloA construct was prepared ( Fig. 5C ) for expression in the N. fumigata easM knockout strain.
Primer combination 7 was used to amplify an intron-free version of cloA with gpdA promoter and 3'UTR extensions from the 1,524 bp cDNA (see mRNA analysis) ( Fig. 4 , Table 2 ). Primer combination 8 was used for PCR amplification of the gpdA promoter with cloA extension from N.
fumigata wild type strain Af293 (Fig. 4 , Table 2 ). No restriction site needed to be assembled to the primer, because the sequence already contained an XbaI restriction site (TCTAGA) near its 5' end ( Fig. 5C ). Equimolar amounts intron-free cloA, gpdA promoter, and 3'UTR (from the previous section) were combined in a fusion PCR, using primer combination 9 ( Fig. 4 , Table 2 ) to form a construct for analyzing the effect of a new, stronger promoter (Fig. 5C ). The gpdA promoter-intron free cloA construct was double-digested with EcoRI and XbaI, then ligated into EcoRI/XbaIdigested pBC-phleo (Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for phleomycin resistance after fungal transformation (Fig. 5C ). The plasmid was transformed into E. coli, plasmid prepped (Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic digests and DNA sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then transformed with the same methods, into the festuclavine-accumulating easM KO strain.
C. gigantea easA-cloA construct
To test whether CloA required a species specific EasA to function properly, an easA-easA/easG promoter-intron free cloA construct was prepared ( Fig. 5D ) for expression in an N.
fumigata easA knockout strain. The bidirectional promoter had to be reamplified using primer combination 10, in order to add on easA and cloA extensions ( Fig. 4 , Table 2 ). The easA segment with bidirectional promoter extension was amplified from C. gigantea DNA using primer combination 11 (Fig. 4 , Table 2 ). The forward primer in the combination was assembled with an oligonucleotide that contained an XbaI restriction site (TCTAGA) near its 5' end to facilitate cloning of the product (Fig. 5D ). The construct was assembled by adding equimolar amounts easA, bidirectional promoter, cloA, and 3'UTR into a fusion PCR, using primer combination 12 ( Fig. 4 , Table 2 ). The reverse primer for the fusion product was assembled with an oligonucleotide that contained a HindIII restriction site (AAGCTT), due to easA from C. gigantea already having an
EcoRI site in its sequence (Fig. 5D ). The easA-cloA construct was double-digested with HindIII and XbaI, then ligated into HindIII/XbaI-digested pBC-phleo (Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for phleomycin resistance after fungal transformation (Fig.   5D ). The plasmid was transformed into E. coli, plasmid prepped (Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic digests and DNA sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then transformed with the same methods, into an easA KO N.
fumigata strain. 
Fungal Transformation
The easA/easG promoter-cloA construct, the easA/easG promoter-intron free cloA construct, and the gpdA promoter-intron free cloA construct were transformed into an N. fumigata easM KO strain, and the easA-easA/easG promoter-intron free cloA construct was transformed into an N. fumigata easA KO strain. All constructs were transformed with a phleomycin resistance vector containing the gene, ble, from Aspergillus niger.
Protoplasts were prepared by growing fungal cultures in 50 mL of malt broth at 37 °C with shaking at 80 rpm overnight. The broth was discarded and replaced with 15 mL 0.7 M NaCl containing 40 mg lysing enzyme (Sigma-Aldrich, St. Louis, MO) and 1 g VinoTaste Pro (Gusmer Enterprises Inc., Mountainside, NJ), then shaken for an additional 2 hours at 37 °C and 80 rpm.
Protoplasts were separated from hyphae by filtering through miracloth and then were pelleted by centrifugation (3 min at 3,000 × rpm). The protoplasts were washed with 10 mL 0.7 M NaCl and 5 mL STC (1 M Sorbitol, 1 M Tris (pH = 7.4), 1 M CaCl2), and then resuspended in a final volume of STC, so that a 100 µL would have 5x10 6 protoplasts. A polyethylene glycol (PEG) solution was prepared by adding 2 volumes of 37.5% PEG 8000 to 1 volume of PEG amendments (1.8 M KCl, 150 mM CaCl2, 150 mM Tris (pH = 7.47)) and was added to the protoplast solution in the amount of ¼ the final volume that the protoplasts are in. Once the final protoplast solution was prepared, 125 µL was added to 10 µL of the desired plasmid and incubated on ice for 30 minutes. An additional 1 mL of PEG solution was added to the solution and incubated at room temperature for 20 minutes. The solution was then split across 3 petri dishes (about 365 µL each) and mixed with 15 mL molten TM102 media (Rykard et al., 1982) . Once solidified, an additional layer of molten TM102 mixed with 800 µg/mL phleomycin (InvivoGen, San Diego, CA) was added. The plates were incubated for 3 days at 37 °C and the blue fungal colonies were replated on malt extract agar plates and analyzed by HPLC with fluorescent detection.
mRNA analysis
Transformed fungal cultures were grown in 50 mL of malt extract broth in a 250-mL Erlenmeyer flask for 1 day at 37°C with shaking at 80 rpm. The produced fungal mat was placed in a petri dish and incubated at 37°C for an additional day. The RNeasy Plant Mini kit (Qiagen, Gaithersburg, MD) was used to extract RNA from approximately 80 mg of fungal mat. RNA was treated with DNaseI (RNeasy Mini kit) in place of step 6 of the protocol and was reverse transcribed with Superscript IV (bypassing the optional RNAse H step). Resulting cDNA was diluted 1:10 and amplified by PCR using Phusion high-fidelity DNA polymerase and primer combination 13 (Table 2) to test for the presence of cloA. The resulting gel showed two bands, so the PCR product was reloaded onto a 0.8% agarose gel and run at 25 V for 4 hours to effectively separate these bands, for easier individual purification with Qiaquick columns. Both purified versions of cDNA were ligated into SmaI-digested pUC18 and transformed into E. coli (Fig. 10B) , in order to have higher concentrations for sequencing, and the resulting plasmids were sent for sequencing (Eurofins, Louisville KY).
Agroclavine feeding study
The ability of cloA from C. gigantea to utilize both festuclavine and agroclavine as precursors was tested by feeding agroclavine to a C. gigantea cloA-bidirectional easA/easG promoter transformed N. fumigata strain. Agroclavine is oxidized to lysergic acid by cloA from 
Compartmentalization study
In order to test whether the substrate and enzymes were being localized in different compartments, a compartmentalization study was conducted. Transformed N. fumigata cultures were grown in 50 mL of malt extract broth in a 250-mL Erlenmeyer flask for 2 days at 37 °C with shaking at 80 rpm for sufficient sporulation. The resulting fungal mat was divided into equal thirds.
Two of the thirds were homogenized with 200 µL 0.1 M phosphate buffer (pH = 7.6; Kim et al., 1981) , and 0.1 M phosphate buffer supplemented with NADPH (7.5 mg/mL), respectively. The homogenized solutions were transferred to 2-mL microcentrifuge tubes, supplemented with 150 µL 0.06% Tween 20, and incubated for 2 hours at 23°C. After incubation, equal parts of HPLCgrade methanol were added to each solution, pelleted by centrifugation, and 90 µL were analyzed by HPLC with fluorescence detection. The remaining third was analyzed for ergot alkaloids as the control.
HPLC and LC-MS analyses of the transformants
Colonies from each transformant were grown on malt agar for 3-5 days. Samples were taken with the wide end of a 1,000 µL pipette tip and alkaloids were extracted with 300 µL HPLC- Hypersil Gold column (Thermo Fisher, 1.9 µm particle size) in a linear gradient of 5% acetonitrile with 0.1% formic acid to 75% acetonitrile with 0.1% formic acid over a 10 minute period with a flow rate of 300 µL/min (Ryan et al., 2013) . Dihydrolysergic acid has an m/z = 271.2 and was eluted at about 7.8 minutes. After an initial full scan of m/z = 200-400, ions of m/z = 271.2 were fragmented and analyzed.
Results
Function of C. gigantea cloA.
A construct for expressing C. gigantea cloA was successfully transformed into the N. fumigata easM KO strain. A total of 52 transformants were obtained from several transformation experiments, and 33 produced a novel peak that co-eluted with dihydrolysergic acid as evidenced by HPLC with fluorescence detection (Fig. 6) . No other novel peaks of significance were observed in the transformants, but relatively large quantities of festuclavine were still observed. The recipient strain, N. fumigata easM KO, accumulated large quantities of festuclavine (data not shown) and nothing that eluted near dihydrolysergic acid ( Fig. 6) The accumulation of dihydrolysergic acid in the transformants was supported by LC-MS analyses in which the cloA-transformed strains produced a parent ion (m/z = 271.2) consistent with the [M+H] + of dihydrolysergic acid (data not shown). The data indicate that CloA catalyzes a six-electron oxidation of festuclavine to dihydrolysergic acid as opposed to stopping at dihydroelymoclavine (Fig. 2) as expected based on the reported ergot alkaloid profile of C.
gigantea (Agurell and Ramstad, 1965) . The accumulation of dihydrolysergic acid, however, was low in comparison to the abundance of festuclavine in the transformed strains. Potential reasons for this low accumulation, as well as attempts to increase the yield of dihydrolysergic acid are discussed below. Analysis of the natural ergot alkaloid profile of C. gigantea. Due to C. gigantea catalyzing the production of dihydrolysergic acid instead of dihydroelymoclavine, three samples of C. gigantea sclerotia (Fig. 3) were obtained from Dr. Carlos De Leon (Monticello, Mexico) and analyzed by HPLC ( Fig. 7) and LC-MS (Fig. 8) for natural alkaloid production to further investigate its ergot alkaloid biosynthetic capacity. Each of the three sclerotia samples accumulated chanoclavine, festuclavine, and dihydrolysergic acid (Fig. 7) . This alkaloid profile differed from that reported by Agurell and Ramstad (1965) , which included chanoclavine, festuclavine, and dihydroelymoclavine. Even though a compound with the mass of dihydroelymoclavine was not detected it is possible the concentration was below the limit of detection. Another possibility is that ergot alkaloid profile varies among isolates of C. gigantea. Characterization of C. gigantea eas gene cluster. The eas gene cluster in the C. gigantea genome was characterized to obtain evidence for the type of ergot alkaloids the fungus was theoretically capable of producing. The eas cluster (GenBank: KY906251) was studied by identifying contigs that contain eas genes by querying the genome's sequence (Panaccione and Schardl, unpublished) with individual eas genes from other Claviceps species. Additional eas genes were identified in the originally identified contigs by blastx comparisons of upstream and downstream portions of the contigs to the nonredundant nucleotide database at NCBI. The eas cluster contained homologs of the following eas genes : dmaW, easF, easC, easE, easD, easA, easG, cloA, lpsA, lpsB , and easH (Fig. 9B) . The gene cluster indicates the fungus was once capable of producing a dihydroergopeptine derivative of dihydrolysergic acid. This hypothesis was supported by the observation that the product of the gene cloA from C. gigantea oxidized carbon 17 of festuclavine to produce dihydrolysergic acid. Approaches to increase production of dihydrolysergic acid. In order to check for cloA's expression and to see if the introns in cloA were being spliced out correctly, mRNA was extracted from the transformants, reverse-transcribed into cDNA, and were sequenced. PCR analyses of cDNA prepared from mRNA from the cloA-transformed strain indicated that approximately half of the mRNA was fully processed, whereas the other half was larger than expected (Fig. 10A) .
Sequencing results identified two versions of mRNA, the larger being 1,621 and the smaller being 1,524 bp. The larger fragment retained 1 out of the 7 introns, specifically intron 4, and the smaller fragment was free of introns and likely responsible for the small conversion of dihydrolysergic acid (Fig. 10 C) . However, the retention of intron 4 results in a frame shift that leads to a stretch of 6 incorrect amino acids, followed by a premature termination codon, causing the loss of 288 amino acids, which presumably renders the resulting protein nonfunctional (Fig. 10D) . It was plausible that cloA mRNA containing intron 4 could be an issue limiting the production of dihydrolysergic acid in the transformed strain. Fig. 6A ) and some with no introns (smaller band in Fig. 6B ). D) Amino acid sequence for cloA and cloA with intron 4 retained. The amino acid sequence after the 5'-splice junction of intron 4 is highlighted yellow.
In an attempt to increase turnover of festuclavine to dihydrolysergic acid, new versions of the cloA expression construct were prepared using the fully processed cDNA as the template. This fully processed version of cloA was expressed by the original N. fumigata easA-easG promoter to test the effectiveness of removing the intron, and was also expressed by a gpdA promoter to analyze if a stronger promoter would increase the accumulation of dihydrolysergic acid. Both constructs were analyzed by HPLC and LC-MS for production of dihydrolysergic acid. HPLC data is shown for both transformed strains (Fig. 12 ), LC-MS data is shown for gpdA promoter-cloA transformed strain to confirm the product is dihydrolysergic acid (Fig. 11 ). LC-MS data for intron free cloA is not shown. The conversion yields of festuclavine to dihydrolysergic acid were similar, indicating the removal of introns (p = 0.58) and a stronger promoter (p = 0.75) did not have a significant impact on production of dihydrolysergic acid (Table 3 ). Since gpdA promoter-cloA transformed strains did not produce larger amounts of dihydrolysergic acid, it did not seem relevant to analyze the expression of cloA in these transformants. In previous studies conducted by Robinson and Panaccione (2014) cloA and easA from Epichloë sp. Lp1 were cotransformed into an N. fumigata easA knockout strain. The gene easA (isomerase) converted chanoclavine-I-aldehyde to agroclavine, the precursor for Lp1 cloA in their study. Since cloA was not transformed individually it was questioned whether CloA requires EasA, preferentially from the same source, to function optimally. The gene easA from C. gigantea was PCR fused to the free end of the bidirectional N. fumigata easA-easG promoter in the intron-free cloA construct. The construct was transformed into an N. fumigata easA KO strain and analyzed via HPLC (Fig. 12 ). The addition of easA (isomerase) from C. gigantea converted chanoclavine to our precursor, festuclavine, which was then oxidized to dihydrolysergic acid by cloA (Fig. 12) .
However, the easA KO strain still contained the gene, easM, the product of which converted festuclavine into fumigaclavine B, which was ultimately converted to fumigaclavine C via the N.
fumigata fumigaclavine pathway (Fig. 12 ). Since festuclavine was also being converted to fumigaclavine C, fumigaclavine C had to be taken into account when calculating the percent conversion of dihydrolysergic acid. Even with the diversion of some of the substrate to fumigaclavine C, the yield of dihydrolysergic acid increased with the addition of C. gigantea easA to the construct (p = 0.01, Table 3 ). Additionally, since it was speculated that CloA was being localized in different subcellular locations than the festuclavine substrate, the strain containing cloA expressed from the gpd promoter was homogenized and the resulting solutions were incubated with 0.06% Tween 20, and either 0.1 M phosphate buffer (pH = 7.6) or 0.1 M phosphate buffer supplemented with NAPDH (7.5 mg/mL). The homogenized solution was analyzed via HPLC and the quantitative data was analyzed using ANOVA and Tukey-Kramer HSD ( Table 4 ). The percent conversion to dihydrolysergic acid was only significantly different between the control and the homogenized solution incubated with phosphate buffer + NADPH. The other two comparisons were not significantly different. 1.6 ± 0.7 A intron-free cloA 2.1 ± 0.5 A gpd promoter 1.9 ± 0.5 A easA-cloA 4.3 ± 1.5 B Values labeled with different capital letters differ significantly in ANOVA (p = 0.01). DHLA = dihydrolysergic acid. Another possible issue that could have been limiting the production of the alkaloid is the temperature at which the transformants were grown, since C. gigantea is only found in two regions in Mexico, both having cool, humid climates. This made it plausible that the C. gigantea enzymes had a different optimal temperature for activity than N. fumigata. Transformed strains were grown at 24 °C, 37 °C, and 50 °C and analyzed by HPLC with fluorescent detection. The optimal temperature for C. gigantea gene expression was 37°C, which is the same optimal temperature for N. fumigata (Table 5 ). CloA, the cloA-transformed strains were fed agroclavine. HPLC analysis showed the agroclavinefed transformants accumulated lysergic acid (15.1) and isolysergic acid (21.2) ( Fig. 13, Table 6 ).
This indicates that CloA from C. gigantea is capable of oxidizing both festuclavine and agroclavine as substrates. ND The cloA mutant strain that was fed agroclavine was significantly different from the other trials in a Wilcoxon/Kruskal-Wallis test with p = 0.003. ND = none detected; LA = lysergic acid.
Discussion
The expression of CloA in an N. fumigata easM knockout strain altered the fungus to imitate the dihydrolysergic acid pathway. Bilovol and Panaccione (2016) synthesized the easM KO strain to demonstrate the role of easM in the N. fumigata fumigaclavine pathway. This transformant also serves as a transformation recipient to investigate the oxidation of festuclavine to dihydroergot alkaloids, based on Barrow et al.'s (1974) finding that festuclavine was a precursor to dihydroergot alkaloids in Claviceps africana and by extension Claviceps gigantea. Agurell and Ramstad (1965) isolated ergot alkaloids from natural C. gigantea, including festuclavine and dihydroelymoclavine. As a result, it was predicted a C. gigantea cloA-transformed strain of N. fumigata would convert festuclavine into dihydroelymoclavine. The mutant strain, however, produced dihydrolysergic acid rather than dihydroelymoclavine. These data support the findings of Robinson and Panaccione (2014) of CloA catalyzing multiple oxidations. It appears the C. gigantea allele of CloA performs a two-electron oxidation of festuclavine to dihydroelymoclavine, followed by two sets of two-electron oxidations to convert dihydroelymoclavine to dihydrolysergic acid. Also consistent with data reported by Robinson and Panaccione (2014) , there was an absence of dihydroelymoclavine and other intermediates in our transformants, further indicating that CloA binds festuclavine and completes successive oxidations, before releasing dihydrolysergic acid. It was also discovered that CloA from C. gigantea was able to utilize both festuclavine and agroclavine as substrates, meaning that it is capable of functioning in both dihydrolysergic acid and lysergic acid pathways.
Due to the unexpected production of dihydrolysergic acid instead of dihydroelymoclavine, alkaloids from samples of C. gigantea sclerotia were analyzed. Surprisingly, in contrast to the findings of Agurell and Ramstad (1965) , data from three different sclerotia showed accumulation of dihydrolysergic acid, which was not thought to be produced in nature. The data however, supported our findings that the product of cloA was responsible for the production of dihydrolysergic acid. Additionally, having dihydrolysergic acid as the ergot alkaloid pathway end product in the fungus was supported by DNA sequence analysis revealing that the gene encoding lysergyl peptide synthetase subunit 1, lpsA, had a frame shift mutation, likely abolishing the genes function. It was predicted that the correction of the lpsA mutation would further the dihydrolysergic acid pathway to dihydroergosine, as observed by Barrow et al. (1974) for the related fungus C.
africana. Nevertheless, C. gigantea is the first discovered ergot fungus to have dihydrolysergic acid as its pathway end product. Furthermore, after cloA was sequenced from cDNA reverse-transcribed from mRNA from the mutant strains, it was discovered that about half of our mRNA was fully processed, containing no introns, whereas the other half of mRNA still contained one of the seven introns, specifically intron four. This discovery was not surprising, considering some of the cloA introns in C. gigantea had unusual 3' splice junctions, with polyA chains followed by a guanine, instead of the conventional YAG. These unusual 3' splice junctions make it plausible that the host strain, N. fumigata, might have problems recognizing the 3' splice and fail to splice out the intron. An intronfree version of cloA to see if the removal of the fourth intron would have an effect on the production of dihydrolysergic acid. The constructs were successfully transformed and still produced dihydrolysergic acid, however there was not a significant difference between the yields in ANOVA (p = 0.58). As a result, it could be concluded that the retention of intron four did not have an effect on the production of dihydrolysergic acid.
Additionally, it was questioned whether a stronger promoter would assist in increasing the expression of cloA, hopefully increasing the turnover of dihydrolysergic acid. The intron-free version of cloA was expressed from an N. fumigata glyceraldehyde-3-phospate dehydrogenase (gpdA) promoter, which was assumed to be stronger than the N. fumigata easA-easG bidirectional promoter, due to its original role for expressing a gene important for glycolysis. These mutant strains also produced dihydrolysergic acid, however there was not a significant difference between the yield produced by this strain compared yield produced by the original strain in ANOVA (p = 0.75). As a result, it could be concluded that a different promoter did not have a significant effect on the production of dihydrolysergic acid.
Moreover, since Robinson and Panaccione (2014) coexpressed CloA with the oxidoreductase, EasA from the same organism, it was questioned whether CloA functionally required coexpression with a species specific EasA to more efficiently generate dihydrolysergic acid. The coexpression of cloA and easA both from C. gigantea in an N. fumigata easA KO produced two-fold more dihydrolysergic acid (p = 0.006), indicating that the two enzymes may interact in the pathway and that cloA from C. gigantea may function better with easA from C. gigantea rather than easA from N. fumigata. This yield was significantly different from the original yield in ANOVA, however it is important to note that the overall yield was still low.
Similarly, it was also predicted that the enzymes and substrates may be localized in separate compartments. To test this, the transformants were homogenized and incubated with tween, and either 0.1 M phosphate buffer (pH = 7.6) or 0.1 M phosphate buffer (pH = 7.6) supplemented with NADPH (7.5 mg/mL). These homogenized solution incubated with 0.1 M phosphate buffer supplemented with NADPH was significantly different in production of dihydrolysergic acid from the control in ANOVA (p = 0.02). However, it cannot be concluded if the enzymes may be localized in a separate compartment than the substrate or if the addition of NADPH helped in the production. It is also important to note that the overall yield from this experiment was also low.
Another possibility that could be effecting the expression of cloA and/or the turnover of dihydrolysergic acid is the random integration of the constructs into the genome, as a result of our traditional transformation methods. Depending on where the construct is integrated it could be highly expressed, lowly expressed, or not even expressed at all. Multiple transformants were analyzed and their conversions of dihydrolysergic acid were averaged in attempts to minimize this issue.
Lastly, it was questioned whether cloA from C. gigantea could oxidize substrates other than festuclavine. Agroclavine was fed to the mutant strains and analyzed the ergot alkaloids secreted into the media by HPLC. As a result, it was discovered that cloA from C. gigantea can oxidize agroclavine to lysergic acid, the same as cloA from Epichloë sp. Lp1 in Robinson and Panaccione's study (2014) . This means that our allele of cloA is capable of oxidizing both festuclavine and agroclavine, making it functional in both the dihydrolysergic acid pathway and in the lysergic acid pathway.
Overall, the potential of the gene cloA from C. gigantea was unlocked to produce the pharmaceutically important ergot alkaloid dihydrolysergic acid by genetically engineering a strain of N. fumigata. Several significant pharmaceuticals, such as nicergoline (Sermion) and pergolide (Permax), are currently being derived from lysergic acid, however semisynthetic derivation from dihydroelymoclavine and/or dihydrolysergic acid would be more efficient. These drugs are pharmaceutically relevant due to their structural similarities to neurotransmitters, allowing them to treat cognitive and neurological disorders, such as migraines, dementia, Alzheimer's, and Parkinson's disease (Morren and Galvez-Jimenez 2010; Baskys and Hou 2007; Winblad et al. 2007; Perez-Lloret and Rascol 2010) . The generation of dihydrolysergic acid in such a fast-growing organism would have a tremendous impact on drug modification and turnover for these pharmaceuticals, when an alternative starting material is created. Additionally, understanding the genes in the pathway could assist in producing libraries of ergot alkaloid derivatives with altered pharmacology.
